To amend title XI of the Social Security Act to alter when biosimilar biological products are eligible for price negotiations under the Medicare program.
Latest Action
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Sponsors
![Rep. Langworthy, Nicholas A. [R-NY-23]](https://bioguide.congress.gov/bioguide/photo/L/L000600.jpg)
Actions
2026-09-28T00:00:00
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2026-09-28T00:00:00
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2026-09-28T00:00:00
Introduced in House
2026-09-28T00:00:00
Introduced in House
Track this bill on CivicBeacon
Get push notifications when this bill is updated, contact your reps, and take action.
